ArticleNature communications2022
Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Immune dysregulation in prolonged Long-COVID: lymphocytes emerge as key mediators of persistent inflammation, exhaustion and cytotoxicity.Journal of translational medicine · 2026Article
- Article
- Activation of Evolutionarily Young Endogenous Retroviruses Is Implicated in COVID-19 Immunopathology.Genes to cells : devoted to molecular & cellular mechanisms · 2025Article
- TIM3 in COVID-19; A potential hallmark?Heliyon · 2024Review
- CCL2-mediated endothelial injury drives cardiac dysfunction in long COVID.Nature cardiovascular research · 2024Article
- Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19.Journal of intensive medicine · 2024Review
- Host Response Changes and Their Association with Mortality in COVID-19 Patients with Lymphopenia.American journal of respiratory and critical care medicine · 2024Article
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- Immunomics in one health: understanding the human, animal, and environmental aspects of COVID-19.Frontiers in immunology · 2024Review
- Endocarditis caused by Aspergillus fumigatus in a patient 9 months after COVID-19 infection recovery: a case report and review of the literature.Journal of medical case reports · 2023Review
- Using autopsies to dissect COVID-19 pathogenesis.Nature microbiology · 2023Review
- Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target.Archives of virology · 2023Review
- Article
- Article
- Polypharmacology of ambroxol in the treatment of COVID-19.Bioscience reports · 2023Article
- Immune checkpoint alterations and their blockade in COVID-19 patients.Blood science (Baltimore, Md.) · 2022Review
- The current status of gene expression profilings in COVID-19 patients.Clinical and translational discovery · 2022Article
- Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures.Current environmental health reports · 2022Review
- T cell perturbations persist for at least 6 months following hospitalization for COVID-19.Frontiers in immunology · 2022Article
- Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Funding
Abstract
A complete diagnostic autopsy is the gold-standard to gain insight into Coronavirus disease 2019 (COVID-19) pathogenesis. To delineate the in situ immune responses to SARS-CoV-2 viral infection, here we perform comprehensive high-dimensional transcriptional and spatial immune profiling in 22 COVID-19 decedents from Wuhan, China. We find TIM-3-mediated and PD-1-mediated immunosuppression as a hallmark of severe COVID-19, particularly in men, with PD-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.